Skip to main content

Table 1 Clinicopathologic characteristics of the 672 patients with metastatic nasopharyngeal carcinoma (NPC)

From: Elevated peripheral blood lymphocyte-to-monocyte ratio predicts a favorable prognosis in the patients with metastatic nasopharyngeal carcinoma

Characteristic

Total (cases)

Deaths [cases (%)]

Unadjusted HR (95 % CI)

P value

Total

672

458

  

Gender

    

Male

546

371 (67.9)

Reference

0.700

Female

126

87 (69.0)

1.05 (0.83, 1.32)

 

Age (years)

    

<46

316

213 (67.4)

Reference

0.124

≥46

356

245 (68.8)

1.16 (0.96, 1.39)

 

T stage*

    

T1-2

273

184 (67.4)

Reference

0.975

T3-4

399

274 (68.7)

1.00 (0.83, 1.20)

 

N stage*

    

N0-1

273

172 (63.0)

Reference

<0.001

N2-3

399

286 (71.7)

1.42 (1.18, 1.72)

 

Metastasis at presentation

    

Absent

375

261 (69.6)

Reference

0.825

Present

297

197 (66.3)

0.98 (0.81, 1.18)

 

Number of metastatic lesions

    

1

105

51 (48.6)

Reference

<0.001

≥2

567

407 (71.8)

2.06 (1.54, 2.77)

 

Bone metastasis

    

Absent

280

196 (70.0)

Reference

0.862

Present

392

262 (66.8)

1.02 (0.85, 1.22)

 

Liver metastasis

    

Absent

443

283 (63.9)

Reference

<0.001

Present

229

175 (76.4)

1.62 (1.34, 1,95)

 

Lung metastasis

    

Absent

462

309 (66.9)

Reference

0.847

Present

210

149 (71.0)

0.98 (0.81, 1.19)

 

Extraregional lymph node metastasis

    

Absent

497

328 (66.0)

Reference

0.060

Present

175

130 (74.3)

1.22 (0.99, 1.49)

 

EBV VCA/IgA

    

<1:80

80

48 (60.0)

Reference

0.413

1:80–1:320

395

270 (68.4)

1.15 (0.84, 1.56)

 

≥1:640

197

140 (71.1)

1.17 (0.85, 1.63)

 

EBV EA/IgA

    

<1:10

128

84 (65.6)

Reference

0.385

1:10–1:20

216

149 (69.0)

0.97 (0.74, 1.27)

 

≥1:40

328

225 (68.6)

0.91 (0.71, 1.16)

 

Lymphocyte count (× 109/L)

    

<1.390

340

250 (73.5)

Reference

0.002

≥1.390

332

208 (62.7)

0.75 (0.63, 0.90)

 

Monocyte count (× 109/L)

    

<0.665

428

263 (61.4)

Reference

<0.001

≥0.665

244

195 (80.0)

2.17 (1.80,2.62)

 

LMR

    

<2.475

335

269 (80.3)

Reference

<0.001

≥2.475

337

189 (56.1)

0.45 (0.37, 0.54)

 
  1. HR, hazard ratio; CI, confidence interval; EBV, Epstein-Barr virus; VCA/IgA, immunoglobulin A against viral capsid antigen; EA/IgA, immunoglobulin A against early antigen; LMR, lymphocyte-to-monocyte ratio. *The American Joint Committee on Cancer (AJCC) 2002 system was used for staging at the diagnosis of NPC